Loading…
No business profile yet.
Size Mani (7730.T) is a Japan Health Care company (Medical Specialties) with a market value of $909M, the 774th largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥1,454 on 6 Nov 2026.
Performance Over six months the shares fell 14.9%, against -13.3% for the median peer and +1.8% for the Japan market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue grew 10.2% over the last twelve months (peer median +10.2%); the operating margin is 30.1% (peer median 10.2%).
Valuation It trades at 18.4× forward earnings against a peer median of 23.6× (7th cheapest of 17).
Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is -12 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 13.2 points above its cost of capital (8.0% WACC).
Next results Next results expected around 13 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | ¥33.0B | ¥33.0B | ¥30.0B | ¥28.5B | ¥24.5B |
| Revenue growth | — | +10% | +5% | +16% | — |
| Gross profit | ¥22.0B | ¥22.0B | ¥18.9B | ¥17.5B | ¥15.1B |
| EBITDA | ¥12.4B | ¥12.4B | ¥10.7B | ¥10.7B | ¥9.16B |
| Net income | ¥7.24B | ¥7.24B | ¥4.64B | ¥6.29B | ¥5.95B |
| Free cash flow | n/a | ¥10.7B | ¥612M | ¥397M | ¥4.52B |
| Capital expenditure | n/a | ¥1.15B | ¥6.67B | ¥7.68B | ¥3.72B |
| Total debt | ¥81.0M | ¥81.0M | ¥76.0M | ¥83.0M | ¥58.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 7730.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.7% | -6.2% | 9th highest of 21 |
| 6-month return | -14.9% | -13.3% | 10th lowest of 21 |
| Distance from 52-week high | -25.6% | -38.7% | 6th highest of 21 |
| Revenue growth (TTM) | +10.2% | +10.2% | 11th highest of 21 |
| Operating margin | 30.1% | 10.2% | 2nd highest of 21 |
| Forward P/E | 18.4× | 23.6× | 7th cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | 1.5% | 6.9% | 6th least demanding of 16 |
| Growth delivered (Del g) | +13.9% | +11.3% | 5th highest of 16 |
| Hurdle (Req g minus delivered) | -12.4 pp | -3.4 pp | 4th least demanding of 16 |
| ROIC minus cost of capital | +13.2 pp | +1.9 pp | 4th highest of 21 |
| EV / EBITDA | 9.4× | 9.8× | 6th cheapest of 11 |
| Net debt / EBITDA | -2.1× | -0.1× | 4th least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Mani 7730.T | Japan | $909M | -15% | +10% | 30% | 18.4× | 1.5% | +13.9% |
| Shanghai Runda Medical Technology 603108.SS | China | $909M | -25% | -12% | -2% | 25.1× | 22.2% | -0.2% |
| Beijing SDL Technology 002658.SZ | China | $910M | -21% | -13% | 9% | 23.6× | 18.0% | +2.9% |
| LifeTech Scientific 1302.HK | Hong Kong | $914M | -18% | +1% | 12% | 23.5× | 13.3% | +15.5% |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $915M | -30% | +36% | 14% | n/a | 47.2% | +17.1% |
| Seegene 096530.KS | South Korea | $915M | +26% | +12% | 13% | 15.9× | -3.4% | -15.9% |
| Aidite (Qinhuangdao) Technology 301580.SZ | China | $919M | -20% | +17% | 18% | 27.1× | 19.9% | +23.3% |
| Bioventus BVS | United States | $894M | +1% | +4% | 10% | 13.1× | 6.9% | +12.1% |
| Safilo SFL.MI | Italy | $890M | +24% | -4% | 9% | 16.0× | -0.5% | +4.7% |
| Cisen Pharmaceutical 603367.SS | China | $890M | -15% | -6% | 8% | 8.3× | -12.9% | -1.3% |
| Caina Technology 301122.SZ | China | $938M | +60% | +61% | 0% | 72.0× | n/a | n/a |
| Shantou Institute of Ultrasonic Instruments 301602.SZ | China | $944M | -19% | +4% | 30% | n/a | 13.1% | +4.6% |
| Modern Dental 3600.HK | Hong Kong | $871M | +19% | +12% | 22% | 8.8× | -7.0% | +11.3% |
| Shenzhen YHLO Biotech 688575.SS | China | $950M | -20% | +3% | 12% | 37.2× | 3.1% | +12.7% |
| Sino Medical Sciences Technology 688108.SS | China | $868M | -35% | +22% | 19% | 69.2× | 31.0% | +9.9% |
| Kuros Biosciences KURN.SW | Switzerland | $953M | +3% | +41% | 6% | 73.8× | n/a | n/a |
| JINS 3046.T | Japan | $865M | -12% | +14% | 10% | 16.6× | -7.2% | +11.7% |
| MedCap MCAP.ST | Sweden | $864M | +6% | +17% | 15% | 26.4× | 2.9% | +20.9% |
| Beijing Hotgen Biotech 688068.SS | China | $966M | -38% | +8% | -94% | n/a | n/a | n/a |
| Menicon 7780.T | Japan | $854M | +12% | +5% | 9% | 19.3× | n/a | n/a |
| Beta Bionics BBNX | United States | $854M | +63% | +44% | -73% | n/a | n/a | n/a |